HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Akabani, G. Articles by Zalutsky, M. R. Search for Related Content PubMed PubMed Citation Articles by Akabani, G. Articles by Zalutsky, M. R.

Dosimetry of ¹³¹I-Labeled 81C6 Monoclonal Antibody Administered into Surgically Created Resection Cavities in Patients with Malignant Brain Tumors

Departments of Radiology, Pathology, Medicine and Surgery, Duke University Medical Center, Durham, North Carolina

Correspondence: For correspondence or reprints contact: Gamal Akabani, PhD, Department of Radiology, Division of Nuclear Medicine, Duke University Medical Center, Box 3808, Durham, NC 27710.

ABSTRACT

The objective of this study was to perform the dosimetry of ¹³¹I-labeled 81C6 monoclonal antibody (MAb) in patients with recurrent malignant brain tumors, treated by direct injections of MAb into surgically created resection cavities (SCRCs). Methods: Absorbed dose estimates were performed for nine patients. Dosimetry was performed retrospectively using probe counts (during patient isolation) and whole-body and SPECT images thereafter. Absorbed doses were calculated for the SCRC interface and for regions of interest (ROIs) 1 and 2 cm thick, measured from the margins of cavity interface. Also, mean absorbed doses were calculated for normal brain, liver, spleen, thyroid gland, stomach, bone marrow and whole body. The average residence time for the SCRC was 111 h (65–200h). Results: The average absorbed dose per unit injected activity (range) to the SCRC interface and ROIs 1 and 2 cm thick from the cavity interface were 31.9 (7.8–84.2), 1.9 (0.7–3.6) and 1.0 (0.4–81) cGy/MBq, respectively. Average absorbed doses per unit administered activity to brain, liver, spleen, thyroid, stomach, bone marrow and whole body were 0.18, 0.03, 0.08, 0.05, 0.02, 0.02 and 0.01 cGy/MBq, respectively. The high absorbed dose delivered to the SCRC interface may have produced an increase in cavity volume independent of tumor progression. Conclusion: At the maximum tolerated dose of 3700 MBq ¹³¹I-labeled 81C6 MAb, the absorbed doses to the SCRC interface and ROIs of 1 and 2 cm thickness were estimated to be 1180, 71 and 39 Gy, respectively. The estimated average absorbed dose to the brain was 6.5 Gy. There was no neurological toxicity and minimal hematologic toxicity at this maximum tolerated administration level.

Key Words: radioimmunotheraphy • brain tumors • dosimetry

This article has been cited by other articles:

				D. A. Reardon, M. R. Zalutsky, G. Akabani, R. E. Coleman, A. H. Friedman, J. E. Herndon II, R. E. McLendon, C. N. Pegram, J. A. Quinn, J. N. Rich, et al. A pilot study: 131I-Antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost Neuro-oncol, April 1, 2008; 10(2): 182 - 189. [Abstract] [Full Text] [PDF]

				j. H. Sampson, R. Raghavan, M. L. Brady, j. M. Provenzale, j. E. Herndon II, D. Croteau, A. H. Friedman, D. A. Reardon, R. E. Coleman, T. Wong, et al. Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions Neuro-oncol, July 1, 2007; 9(3): 343 - 353. [Abstract] [Full Text] [PDF]

				J. H. Sampson, R. Raghavan, J. M. Provenzale, D. Croteau, D. A. Reardon, R. E. Coleman, I. R. Ponce, I. Pastan, R. K. Puri, and C. Pedain Induction of Hyperintense Signal on T2-Weighted MR Images Correlates with Infusion Distribution from Intracerebral Convection-Enhanced Delivery of a Tumor-Targeted Cytotoxin Am. J. Roentgenol., March 1, 2007; 188(3): 703 - 709. [Abstract] [Full Text] [PDF]

				D. A. Reardon, J. A. Quinn, G. Akabani, R. E. Coleman, A. H. Friedman, H. S. Friedman, J. E. Herndon II, R. E. McLendon, C. N. Pegram, J. M. Provenzale, et al. Novel Human IgG2b/Murine Chimeric Antitenascin Monoclonal Antibody Construct Radiolabeled with 131I and Administered into the Surgically Created Resection Cavity of Patients with Malignant Glioma: Phase I Trial Results J. Nucl. Med., June 1, 2006; 47(6): 912 - 918. [Abstract] [Full Text] [PDF]

				D. A. Reardon, G. Akabani, R. E. Coleman, A. H. Friedman, H. S. Friedman, J. E. Herndon II, R. E. McLendon, C. N. Pegram, J. M. Provenzale, J. A. Quinn, et al. Salvage Radioimmunotherapy With Murine Iodine-131-Labeled Antitenascin Monoclonal Antibody 81C6 for Patients With Recurrent Primary and Metastatic Malignant Brain Tumors: Phase II Study Results J. Clin. Oncol., January 1, 2006; 24(1): 115 - 122. [Abstract] [Full Text] [PDF]

				J. Baranowska-Kortylewicz, M. Abe, K. Pietras, Z. P. Kortylewicz, T. Kurizaki, J. Nearman, J. Paulsson, R. L. Mosley, C. A. Enke, and A. Ostman Effect of Platelet-Derived Growth Factor Receptor-{beta} Inhibition with STI571 on Radioimmunotherapy Cancer Res., September 1, 2005; 65(17): 7824 - 7831. [Abstract] [Full Text] [PDF]

				G. Akabani, D. A. Reardon, R. E. Coleman, T. Z. Wong, S. D. Metzler, J. E. Bowsher, D. P. Barboriak, J. M. Provenzale, K. L. Greer, D. DeLong, et al. Dosimetry and Radiographic Analysis of 131I-Labeled Anti-Tenascin 81C6 Murine Monoclonal Antibody in Newly Diagnosed Patients with Malignant Gliomas: A Phase II Study J. Nucl. Med., June 1, 2005; 46(6): 1042 - 1051. [Abstract] [Full Text] [PDF]

				M. R. Zalutsky Current Status of Therapy of Solid Tumors: Brain Tumor Therapy J. Nucl. Med., January 1, 2005; 46(1_suppl): 151S - 156S. [Abstract] [Full Text] [PDF]

				D. A. Rizzieri, G. Akabani, M. R. Zalutsky, R. E. Coleman, S. D. Metzler, J. E. Bowsher, B. Toaso, E. Anderson, A. Lagoo, S. Clayton, et al. Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma Blood, August 1, 2004; 104(3): 642 - 648. [Abstract] [Full Text] [PDF]

				D. A. Reardon, G. Akabani, R. Edward Coleman, A. H. Friedman, H. S. Friedman, J. E. Herndon II, I. Cokgor, R. E. McLendon, C. N. Pegram, J. M. Provenzale, et al. Phase II Trial of Murine 131I-Labeled Antitenascin Monoclonal Antibody 81C6 Administered Into Surgically Created Resection Cavities of Patients With Newly Diagnosed Malignant Gliomas J. Clin. Oncol., March 1, 2002; 20(5): 1389 - 1397. [Abstract] [Full Text] [PDF]

				I. Cokgor, G. Akabani, C.-T. Kuan, H. S. Friedman, A. H. Friedman, R. E. Coleman, R. E. McLendon, S. H. Bigner, X.-G. Zhao, A. M. Garcia-Turner, et al. Phase I Trial Results of Iodine-131-Labeled Antitenascin Monoclonal Antibody 81C6 Treatment of Patients With Newly Diagnosed Malignant Gliomas J. Clin. Oncol., November 15, 2000; 18(22): 3862 - 3872. [Abstract] [Full Text] [PDF]